2022
DOI: 10.1177/13524585221102158
|View full text |Cite
|
Sign up to set email alerts
|

Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients

Abstract: Background: Development of long-lasting anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) T-cell responses in persons with multiple sclerosis (pwMS) treated with ocrelizumab is questioned. Objective: Investigate antiviral T-cell responses after infection with SARS-CoV-2 in ocrelizumab-treated pwMS. Control groups included ocrelizumab-treated pwMS without SARS-CoV-2 infection, and non-MS individuals with and without SARS-CoV-2 infection. Methods: Peripheral blood mononuclear cells were stimulated… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 8 publications
(10 citation statements)
references
References 21 publications
1
9
0
Order By: Relevance
“…Our results contrast with what has been reported to date regarding the SARS-CoV-2–specific T-cell response. These data show that OCRE does not impair a de novo induction of new virus-specific effector cellular immune response such as extensively reported in the context of vaccination against 22 , 24 - 31 or infection by SARS-CoV-2. 47 - 49 Here, we do not claim that a patient on OCRE is not able to mount a virus-specific immune response; however, our longitudinal systematic study suggests that the persistence of a classical CM immune response such as a CEF-specific CD8 + T-cell response is impaired.…”
Section: Discussionsupporting
confidence: 74%
See 1 more Smart Citation
“…Our results contrast with what has been reported to date regarding the SARS-CoV-2–specific T-cell response. These data show that OCRE does not impair a de novo induction of new virus-specific effector cellular immune response such as extensively reported in the context of vaccination against 22 , 24 - 31 or infection by SARS-CoV-2. 47 - 49 Here, we do not claim that a patient on OCRE is not able to mount a virus-specific immune response; however, our longitudinal systematic study suggests that the persistence of a classical CM immune response such as a CEF-specific CD8 + T-cell response is impaired.…”
Section: Discussionsupporting
confidence: 74%
“…21 Indeed, one can observe markedly attenuated humoral responses in OCRE-treated pwMS after COVID-19 infection or after vaccination by mRNA vaccine. [22][23][24][25][26] By contrast, SARS-CoV-2-specific CD4 + and CD8 + T-cell responses do not seem to be affected, 22,[24][25][26][27][28][29][30][31] although selective deficits in circulating follicular helper T cells are reported. 22 Nevertheless, up to now, not much is known regarding the maintenance of the virus-specific memory T-cell recall responses on OCRE, which raises the question whether this cellular immune response might be involved in the reported increased risk of infection on OCRE.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, even if antibody-mediated immune response to SARS-CoV-2 was reported to be reduced in patients receiving anti-CD20 monoclonal antibodies, an effective cell-mediated immune response may contribute to the protection against COVID-19 in these cases. This was recently suggested by the observation that pwMS treated with anti-CD20 therapies developed a long-lasting anti-SARS-CoV-2 T-cell response after COVID-19, with levels similar to infected persons without MS ( Guerrera et al, 2022 ).…”
Section: Discussionmentioning
confidence: 90%
“… 22 , 24 , 25 However, it is interesting to underline that while ocrelizumab‐treated pwMS still retain the ability to elicit a vaccine‐specific T‐cell response, fingolimod treatment impedes the generation of both humoral and cellular response to vaccination. 22 , 24 , 26 …”
Section: Discussionmentioning
confidence: 99%
“…22,24,25 However, it is interesting to underline that while ocrelizumab-treated pwMS still retain the ability to elicit a vaccine-specific T-cell response, fingolimod treatment impedes the generation of both humoral and cellular response to vaccination. 22,24,26 To evaluate whether the identified early immune module induced by mRNA vaccine was induced also in pwMS, we enrolled a group of relapsing remitting MS patients before starting the immunisation with the anti-COVID-19 BNT162b2 mRNA vaccine, that were longitudinally followed up to the second vaccine dose. When we analysed the entire group, independently of administered DMT, similarly to healthy vaccine recipients, a vaccine-induced early immune signature was found, in terms of IFN-induced gene transcription and serum cytokine and chemokine content, positively correlating with protective humoral response.…”
Section: Discussionmentioning
confidence: 99%